Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study in Italy

ClinicalTrials.gov Identifier: NCT05376579

Novartis Reference Number: CBAF312AIT04

Last Update: Nov 18, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This is an observational, multicenter, single-arm, prospective study conducted in Italy

Condition 
Active Secondary Progressive Multiple Sclerosis
Phase 
Not Given
Overall status 
Recruiting
Start date 
Jun 17, 2022
Completion date 
Jun 30, 2026
Gender 
All
Age(s)
18 Years - 60 Years (Adult)

Interventions

Other
siponimod
Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.

Eligibility Criteria

Inclusion Criteria:

Signed informed consent: patient must provide written informed consent before any study assessment is performed.
Male/female participants aged between 18 and 60.
Documented diagnosis of active SPMS.
Siponimod treatment as routine medical care: patients newly treated with siponimod (starting not more than 7 days before baseline visit), for whom the decision to start treatment has already been taken independently of study inclusion based on clinical practice and according to SmPC and AIFA criteria, and who successfully qualified for treatment with siponimod (i.e. passed the screening procedure mandated by the SmPC and Risk Management Plan (RMP) for this treatment, including genotyping for CYP2C9 to determine CYP2C9 metaboliser status).

Exclusion Criteria:

Patients treated outside the approved siponimod label or with any controindication indicated in the SmPC.
Pregnant or lactating women.
Patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the investigator's judgement.
Current participation in an interventional trial.
Treatment with siponimod prior to inclusion in this study (siponimod can be started not more than 7 days before baseline visit).

Study Locations

Italy
Novartis Investigative Site
Recruiting
Ancona, 60126
AN
Italy
Novartis Investigative Site
Recruiting
L Aquila, 67100
AQ
Italy
Novartis Investigative Site
Recruiting
Bergamo, 24128
BG
Italy
Novartis Investigative Site
Recruiting
Bologna, 40139
BO
Italy
Novartis Investigative Site
Recruiting
Brescia, 25123
BS
Italy
Novartis Investigative Site
Recruiting
Como, 22100
CO
Italy
Novartis Investigative Site
Recruiting
Foggia, 71100
FG
Italy
Novartis Investigative Site
Recruiting
Messina, 98121
ME
Italy
Novartis Investigative Site
Recruiting
Milano, 20133
MI
Italy
Novartis Investigative Site
Recruiting
Palermo, 90127
PA
Italy
Novartis Investigative Site
Recruiting
Pisa, 56126
PI
Italy
Novartis Investigative Site
Recruiting
Pavia, 27100
PV
Italy
Novartis Investigative Site
Recruiting
Roma, 00133
RM
Italy
Novartis Investigative Site
Recruiting
Roma, 00152
RM
Italy
Novartis Investigative Site
Recruiting
Roma, 00189
RM
Italy
Novartis Investigative Site
Recruiting
Trieste, 34149
TS
Italy
Novartis Investigative Site
Recruiting
Vicenza, 36100
VI
Italy
Novartis Investigative Site
Recruiting
Novara, 28100
-
Italy

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]